(38 days)
Not Found
Not Found
No
The document describes a susceptibility testing plate and its intended use with specific antibiotics for certain bacterial species. There is no mention of AI, ML, image processing, or any other technology typically associated with AI/ML in medical devices. The focus is on the chemical and biological aspects of the test.
No
This device is described as an "in vitro diagnostic product for clinical susceptibility testing," indicating it is used to diagnose or monitor conditions rather than to treat them.
Yes
The document explicitly states that the Sensititre® Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC Susceptibility plate is "an in vitro diagnostic product for clinical susceptibility testing".
No
The device description is not provided, but the intended use clearly describes an in vitro diagnostic product (a physical plate) for susceptibility testing, which is a hardware component.
Yes, this device is an IVD (In Vitro Diagnostic).
The "Intended Use / Indications for Use" section explicitly states:
"The Sensitire® Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC Susceptibility plate is an in vitro diagnostic product for clinical susceptibility testing of Haemophilus influenzae, Streptococcus pneumoniae and Streptococcus species."
This statement directly identifies the device as an in vitro diagnostic product.
N/A
Intended Use / Indications for Use
The Sensitire® Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC Susceptibility plate is an in vitro diagnostic product for clinical susceptibility testing of Haemophilus influenzae, Streptococcus pneumoniae and Streptococcus species.
This 510(k) is for the addition of Streptococcus spps to Cefuroxime (0.5 -4 ug/mL), Gatifloxacin (1-8 ug/mL), Erythromycin (0.25-1 ug/ml) for use with the Sensititre® Haemophilus influenzae/Streplooccus pneumoniae (HP) MIC Susceptibility Plates.
The approved primary "indications for use" and clinical significance of Cefuroxime is for: Streptococcus pneumoniae, Streptococcus pyogenes
The approved primary "indications for use" and clinical significance of Gatifloxacin is for Streptococcus pneumoniae, Streptococcus pyogenes
The following in vitro data are available but their clinical significance is unknown:
_Viridans group streptococci
Streptococcus agalactiae
The approved primary "indications for use" and clinical significance of Erythromycin is for: Streptococcus pneumoniae Streptococcus pyogenes
Product codes
JWY, LRG
Device Description
Sensititre® Haemophilus influenza/Streptococcus pneumoniae (HP) MIC susceptibility plates, for Cefuroxime (0.5-4 ug/ml), Gatifloxacin (1 - 8 ug/ml), Erythromycin (0.25 - 2 µg/ml)
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.1640 Antimicrobial susceptibility test powder.
(a)
Identification. An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.(b)
Classification. Class II (performance standards).
0
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/0/Picture/1 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features a stylized caduceus, a symbol often associated with medicine and healthcare, consisting of a staff with two snakes coiled around it. The seal is encircled by the words "DEPARTMENT OF HEALTH & HUMAN SERVICES . USA" in a circular arrangement.
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
OCT 2 0 2006
Ms. Cynthia C. Knapp Director Lab Services TREK Diagnostic Systems, Inc. 982 Keynote Circle, Suite 6 Cleveland, OH 44131
Re: K062722
Trade/Device Name: Sensititre® Haemophilus influenza/Streptococcus pneumoniae (HP) MIC susceptibility plates, for Cefuroxime (0.5-4 ug/ml), Gatifloxacin (1 - 8 ug/ml), Erythromycin (0.25 - 2 µg/ml) Regulation Number: 21 CFR 866.1640 Regulation Name: Antimicrobial Susceptibility Test Powder Regulatory Class: Class II Product Code: JWY, LRG Dated: September 11, 2006 Received: September 12, 2006
Dear Ms. Knapp:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the includions for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical In Including of to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, Internet of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations areemig not ticently your ticence may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
1
This letter will allow you to begin marketing vour device as described in your Section 510/k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Sally artman
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known): K062722
Device Name: Sensititre® Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC Susceptibility Plates. Cefuroxime (0.5-4µg/ml), Gatifloxacin (1-8 µg/ml), Erythromycin (0.25-2 µg/ml),
Indications For Use:
The Sensitire® Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC Susceptibility plate is an in vitro diagnostic product for clinical susceptibility testing of Haemophilus influenzae, Streptococcus pneumoniae and Streptococcus species.
This 510(k) is for the addition of Streptococcus spps to Cefuroxime (0.5 -4 ug/mL), Gatifloxacin (1-8 ug/mL), Erythromycin (0.25-1 ug/ml) for use with the Sensititre® Haemophilus influenzae/Streplooccus pneumoniae (HP) MIC Susceptibility Plates .
The approved primary "indications for use" and clinical significance of Cefuroxime is for: Streptococcus pneumoniae, Streptococcus pyogenes
The approved primary "indications for use" and clinical significance of Gatifloxacin is for Streptococcus pneumoniae,
Streptococcus pyogenes
The following in vitro data are available but their clinical significance is unknown:
_Viridans group streptococci
Streptococcus agalactiae
The approved primary "indications for use" and clinical significance of Erythromycin is for: Streptococcus pneumoniae Streptococcus pyogenes
Prescription Use _ X
AND/OR
Over-The-Counter Use
(Part 21 CFR 801 Subpart D)
(21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic De
Diagnostic Devices (OIVD)
Freddie Tu. Poole
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and
7100(k) K062725